More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.88B
EPS
-15.16
P/E ratio
--
Price to sales
5.65
Dividend yield
--
Beta
0.341529
Previous close
$80.28
Today's open
$81.35
Day's range
$77.39 - $81.35
52 week range
$53.89 - $91.53
show more
CEO
Bobak Azamian
Employees
370
Headquarters
Irvine, CA
Exchange
Nasdaq Global Select
Shares outstanding
49305552
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
GlobeNewsWire • Nov 5, 2026

Tarsus Pharmaceuticals Q3 Earnings Call Highlights
Tarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye care professionals and a growing contribution from retreatment prescriptions.
MarketBeat • Nov 4, 2026

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Tarsus Reports Third Quarter 2026 Financial Results
Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch Appointed Neera Clase as Chief Commercial Officer Management to host conference call today, November 3, 2026, at 1:30 p.m. PT / 4:30 p.m.
GlobeNewsWire • Nov 3, 2026

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to a loss of $0.3 per share a year ago.
Zacks Investment Research • Nov 4, 2026

How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • Nov 2, 2026

My 'Eye' Is On Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is well-positioned with Xdemvy's rapid commercial ramp and robust $2B peak sales potential. Recent acquisitions of IRX-101 and ALK-101 diversify the pipeline, adding both low-risk and high-reward late-stage assets. IRX-101's clinical data and market need suggest strong approval prospects and $600–900M peak sales, enhancing TARS' valuation case.
Seeking Alpha • Nov 1, 2026

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.
GlobeNewsWire • Oct 29, 2026

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served as Tarsus' Interim Chief Commercial Officer since July 2026 and previously served as Senior Vice President of Market Access.
GlobeNewsWire • Oct 28, 2026

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Tarsus Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.